Hatakeyama Yutaka, Horino Taro, Yasui Shigehiro, Komori Masahiro, Terada Yoshio, Okuhara Yoshiyasu
Center of Medical Information Science, Kochi Medical School, Kochi University, Kohasu, Oko-Cho, Nankoku, Kochi, 783-8505, Japan.
Department of Endocrinology, Metabolism and Nephrology, Kochi Medical School, Kochi University, Kohasu, Oko-Cho, Nankoku, Kochi, 783-8505, Japan.
Clin Exp Nephrol. 2023 Mar;27(3):262-271. doi: 10.1007/s10157-022-02303-z. Epub 2022 Dec 27.
The epidemiology of renal impairment in patients with cancer remains unclear. We aimed to clarify associations between various cancer sites and renal impairment.
We reviewed data from 5674 patients aged ≥ 18 years receiving cancer treatment at a single hospital facility. The primary endpoints were the occurrence of acute kidney injury (AKI), a 30% decrease in the estimated glomerular filtration rate (eGFR), or death. Survival time was defined as the time from study enrolment to AKI occurrence. Kaplan-Meier and Cox proportional hazard analyses were performed.
Hazard ratios (HRs) for AKI occurrence and a ≥ 30% decline in eGFR were significantly higher for kidney, urinary tract, pancreatic, liver, and gallbladder cancers than for colon cancer. Compared with colon cancer, digestive tract cancer showed a significantly higher HR for AKI occurrence alone. The HRs for a ≥ 30% decline in eGFR were significantly higher for patients aged 71‒77 years or ≥ 78 years than for those aged < 68 years, and for patients with eGFR ≥ 90 mL/min/1.73 m or 30-44 mL/min/1.73 m than for those with eGFR = 45‒59 mL/min/1.73 m.
Kidney, urinary, hepatobiliary, or pancreatic cancer are associated with a higher risk of AKI development and eGFR decrease than other cancers. Renal function changes should be more closely monitored in patients with these cancers.
癌症患者肾功能损害的流行病学情况仍不清楚。我们旨在阐明不同癌症部位与肾功能损害之间的关联。
我们回顾了在一家医院接受癌症治疗的5674例年龄≥18岁患者的数据。主要终点为急性肾损伤(AKI)的发生、估计肾小球滤过率(eGFR)下降30%或死亡。生存时间定义为从研究入组到发生AKI的时间。进行了Kaplan-Meier和Cox比例风险分析。
肾癌、尿路癌、胰腺癌、肝癌和胆囊癌发生AKI以及eGFR下降≥30%的风险比(HR)显著高于结肠癌。与结肠癌相比,消化道癌仅发生AKI的HR显著更高。年龄在71-77岁或≥78岁的患者以及eGFR≥90 mL/min/1.73 m²或30-44 mL/min/1.73 m²的患者,其eGFR下降≥30%的HR显著高于年龄<68岁的患者以及eGFR = 45-59 mL/min/1.73 m²的患者。
肾癌、尿路癌、肝胆癌或胰腺癌与发生AKI和eGFR降低的风险高于其他癌症。对于这些癌症患者,应更密切监测肾功能变化。